🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against superbug strains of the pathogen, according to researchers.

A Global Challenge

The sexually transmitted infection are escalating worldwide, with data suggesting more than 82 million infections annually. Notably increased rates are seen in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the reality of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Approval

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This drug, which is employed against UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per findings released by a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This places it at an comparable level with the current standard treatment, which combines a dual-drug approach. The study involved hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals treating patients have voiced hope. Having a single-dose, oral treatment such as this is hailed as a "revolutionary step" for gonorrhoea control. This is deemed crucial to reduce the burden of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.